Alkermes Stock Forecast
NASDAQ: ALKSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
ALKS analyst consensus
Consensus (19 analysts)
buy
Avg. price target
$56.56+36.47%
- Strong buy 3
- Buy 11
- Hold 4
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 19 Wall Street analysts covering Alkermes (2026-10-07), 14 rate the stock a buy or strong buy, 4 rate it a hold and 1 rate it a sell or strong sell, for a consensus rating of "buy". The average 12-month price target is $56.56, with a high estimate of $83.00 and a low estimate of $38.00. The average target implies upside of 36.5% from the current price of $41.45.
The spread between the highest and lowest targets is 118.4%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for ALKS.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 3 | 16% |
| Buy | 11 | 58% |
| Hold | 4 | 21% |
| Sell | 0 | 0% |
| Strong sell | 1 | 5% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $38.00 | -8.31% |
| Average target | $56.56 | +36.47% |
| High target | $83.00 | +100.27% |